Pre-Clinical Assessment of (177)Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease

Схожие документы

• Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts
  по: Yong, Kwon Joong, et al.
  Опубликовано: (2016)
• Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease
  по: Milenic, Diane E, et al.
  Опубликовано: (2015)
• Targeted α-Particle Radiation Therapy of HER1-Positive Disseminated Intraperitoneal Disease: An Investigation of the Human Anti-EGFR Monoclonal Antibody, Panitumumab
  по: Milenic, Diane E., et al.
  Опубликовано: (2017)
• Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
  по: Kwon Joong Yong, et al.
  Опубликовано: (2016-01-01)
• Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and (212)Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model
  по: Yong, Kwon Joong, et al.
  Опубликовано: (2016)